Quality of life study in asymptomatic patients with hepatitis C

López, Raúl Honrubia; Portales, Miriam Romero; Sánchez, A; Grau, P. Castillo; Sosa, José Carlos Erdozaín; Martín, Antonio Olveira; García-Samaniego, Javier

doi:10.17235/reed.2019.6339/2019

Rev Esp Enferm Dig

2019

DOI: 10.17235/reed.2019.6339/2019

|View full text |Cite

Quality of life study in asymptomatic patients with hepatitis C

Raúl Honrubia López

Miriam Romero Portales

A Sánchez

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is unknown whether transplant candidates considering HCV-RNA + donor lungs have concerns about worse QOL because of adverse physical effects of HCV infection or from anxiety about being cured. [13][14][15] The primary aim of the SHELTER trial was to determine safety and effectiveness of transplanting lungs from HCV-RNA + donors into HCV-negative patients. We also collected prospective data on QOL using the validated RAND-36 instrument.…”

mentioning

confidence: 99%

The SHELTER Trial of Transplanting Hepatitis C Virus–Infected Lungs Into Uninfected Recipients

Reese

Diamond

Goldberg

et al. 2023

Transplantation Direct

View full text Add to dashboard Cite

Background. SHELTER is a trial of transplanting lungs from deceased donors with hepatitis C virus (HCV) infection into HCV-negative candidates (sponsor: Merck; NCT03724149). Few trials have reported outcomes using thoracic organs from HCV-RNA+ donors and none have reported quality of life (QOL). Methods. This study is a single-arm trial of 10 lung transplants at a single center. Patients were included who were between 18 and 67 y of age and waitlisted for lung-only transplant. Patients were excluded who had evidence of liver disease. Primary outcome was HCV cure (sustained virologic response 12 wk after completing antiviral therapy). Recipients longitudinally reported QOL using the validated RAND-36 instrument. We also applied advanced methods to match HCV-RNA+ lung recipients to HCV-negative lung recipients in a 1:3 ratio at the same center. Results. Between November 2018 and November 2020, 18 patients were consented and opted-in for HCV-RNA+ lung offers in the allocation system. After a median of 37 d (interquartile range [IQR], 6–373) from opt-in, 10 participants received double lung transplants. The median recipient age was 57 y (IQR, 44–67), and 7 recipients (70%) had chronic obstructive pulmonary disease. The median lung allocation score at transplant was 34.3 (IQR, 32.7–86.9). Posttransplant, 5 recipients developed primary graft dysfunction grade 3 on day 2 or 3, although none required extracorporeal membrane oxygenation. Nine patients received elbasvir/grazoprevir, whereas 1 patient received sofosbuvir/velpatasvir. All 10 patients were cured of HCV and survived to 1 y (versus 83% 1-y survival among matched comparators). No serious adverse events were found to be related to HCV or treatment. RAND-36 scores showed substantial improvement in physical QOL and some improvement in mental QOL. We also examined forced expiratory volume in 1 s—the most important lung function parameter after transplantation. We detected no clinically important differences in forced expiratory volume in 1 s between the HCV-RNA+ lung recipients versus matched comparators. Conclusions. SHELTER adds important evidence regarding the safety of transplanting HCV-RNA+ lungs into uninfected recipients and suggests QOL benefits.

show abstract

mentioning

confidence: 99%

The SHELTER Trial of Transplanting Hepatitis C Virus–Infected Lungs Into Uninfected Recipients

Reese

Diamond

Goldberg

et al. 2023

Transplantation Direct

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Quality of life study in asymptomatic patients with hepatitis C

Cited by 1 publication

References 15 publications

The SHELTER Trial of Transplanting Hepatitis C Virus–Infected Lungs Into Uninfected Recipients

The SHELTER Trial of Transplanting Hepatitis C Virus–Infected Lungs Into Uninfected Recipients

Contact Info

Product

Resources

About